| 09th week of 2016 patent applcation highlights part 10 |
| Patent application number | Title | Published |
|---|
| 20160058824 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES - In alternative embodiments the invention provides compositions and methods for ameliorating diseases and conditions having a beta-amyloid component, including Alzheimer's disease (AD), Vascular Dementia (VD), dementia, pre-dementia, Cognitive Dysfunction Syndrome (CDS) and loss of cognition in humans and in non-human animal. In alternative embodiment the invention provides analogs of AB-007 and its acid form E64c (loxistatin), their preparation, and pharmaceutical compositions thereof and methods of making and using same. In alternative embodiments compositions of the invention are deuterated analogs of AB-007 (or E64d) and E64c (or loxistatin). In alternative embodiments compositions of the invention are metabolically blocked forms as compared to AB-007 and loxistatin. In alternative embodiments compositions of the invention are used to ameliorate (including treat, slow, reverse or prevent) a disease or condition which can be ameliorated by partial or complete inhibition of a cysteine protease, e.g., AD, VD, CDS. The invention also provides alternative dosage forms and formulations for AB-007 and loxistatin, and for compounds of this invention, which can be used e.g., to treat AD, VD and CDS, in humans and in non-human animals. | 2016-03-03 |
| 20160058825 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS - The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pi gmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. | 2016-03-03 |
| 20160058826 | MITOCHONDRIAL-TARGETED ANTIOXIDANTS PROTECT AGAINST MECHANICAL VENTILATION-INDUCED DIAPHRAGM DYSFUNCTION AND SKELETAL MUSCLE ATROPHY - The present disclosure provides methods and compositions for preventing or treating MV-induced or disuse-induced skeletal muscle infirmities in a mammalian subject. The methods further include administering to the subject an effective amount of an aromatic-cationic peptide. | 2016-03-03 |
| 20160058827 | COMBINATION ANTI-ESTROGEN RECEPTOR CANCER THERAPY USING MUC1 PEPTIDES AND CHEMOTHERAPEUTICS - The invention provides for treatment of MUC1+/ERα+/− cancers using an anti-MUC1 therapy, optionally including an anti-ERα therapy. In particular, the invention addresses the treatment of tamoxifen-resistant cancers, using MUC1+, and optionally anti-ERα therapy. | 2016-03-03 |
| 20160058828 | METHODS, USES AND COMPOSITIONS OF TIE2 AGONISTS - The present disclosure provides methods and uses of Tie2 agonists alone or in combination with antiviral agents. In particular, the present disclosure provides methods and uses for treating influenza, treating a bacterial superinfection associated with influenza and decreasing lung endothelial leakage. The disclosure also provides compositions comprising (a) a Tie2 agonist and (b) an antiviral agent and methods and uses thereof. | 2016-03-03 |
| 20160058829 | ANTI-FIBROTIC PEPTIDES AND THEIR USE IN METHODS FOR TREATING DISEASES AND DISORDERS CHARACTERIZED BY FIBROSIS - The invention provides methods and compositions for inhibiting and/or reversing fibrosis. The invention further provides peptides and polypeptides which are BMP agonists which trigger BMP signaling and inhibit and/or reverse EMT in a cell or tissue. | 2016-03-03 |
| 20160058830 | Therapy and Prevention of Problem Drinking - The present invention provides methods for the therapy and prevention of problem drinking in alcohol-dependent and non-dependent subjects and those at risk of developing problem drinking behavior, and compositions of matter comprising oxytocin or an analog or derivative thereof or an agonist or partial agonist of an oxytocin receptor that are useful in preventing or treating problem drinking. | 2016-03-03 |
| 20160058831 | LEARNING MOTIVATION IMPROVERS - The present invention aims to provide antidepressants which are free from the problem of side effects and are excellent in safety. The present invention also aims to provide learning motivation improvers which are useful for improvement of learning motivation and can be ingested continuously. | 2016-03-03 |
| 20160058832 | MEDICAL USE OF SYNDECAN-2 - SDC2, compositions that comprise SDC2, vectors encoding SDC2 and compounds that modulate expression of SDC2 by cells are used for treatment of mammalian, e.g. human, cells to achieve immunomodulation or for other specific therapeutic interventions. Cells are treated by combining the cells with SDC2, treating the cells with an antibody or fragment thereof that binds SDC2 or modulating expression or activity of SDC2 by the cells. Cells or tissue are derived from treated cells for therapeutic uses based on their immunomodulatory or other therapeutic properties. | 2016-03-03 |
| 20160058833 | Composition Including the HIP/PAP Protein or One of the Derivatives Thereof for Treating Insulin Resistance - The invention relates to a HIP/PAP protein or to one of the derivatives thereof for use thereof for treating or preventing insulin resistance in non-insulin dependent subjects. | 2016-03-03 |
| 20160058834 | FORMULATIONS AND METHODS OF USE FOR ALPHA CONNEXIN C-TERMINAL (ACT) PEPTIDES - This invention relates to a topical gel drug product preparation containing a composition comprising an isolated polypeptide having a carboxy-terminal amino acid sequence of an alpha connexin (ACT peptide), peptide stabilizers, excipients, buffering agents, and the like. A formulation and preparation steps are disclosed for the manufacturing of a stable, elegant, and pourable topical gel. The resulting formulation possesses long term stability suitable for aesthetic as well as therapeutic applications including the prevention of scaring and accelerated healing of wounds. Methods for treatment of chronic wounds, including chronic ulcers, are also provided. | 2016-03-03 |
| 20160058835 | USE OF TAENIA SOLIUM RECOMBINANT CALRETICULIN FOR INDUCING INTERLEUKIN-10 EXPRESSION - The present invention is related to the use of a recombinant protein to induce interleukin 10 expression, wherein the protein is | 2016-03-03 |
| 20160058836 | IK FACTOR AND PHARMACEUTICAL USE OF NUCLEIC ACID ENCODING IK FACTOR - The present invention relates to a pharmaceutical composition for treating and/or preventing arthritis, which comprising, as an active ingredient, a gene delivery vehicle into which an IK factor or a fragment thereof, or a nucleic acid encoding thereof is inserted. IK factor or the fragment thereof, and the nucleic acid encoding thereof, which are the active ingredient of the pharmaceutical composition according to the present invention, are derived from an organism and therefore, show no side effects in administered into a subject for a long time. Accordingly, they ensures safety and are expected to effectively treat arthritis by being involved in the upstream mechanism for suppressing arthritis. | 2016-03-03 |
| 20160058837 | METHODS OF USING SECONDARY LYMPHOID ORGAN CHEMOKINE TO MODULATE PHYSIOLOGICAL PROCESSES IN MAMMALS - The invention is based on the disclosure provided herein that secondary lymphoid organ chemokine (SLC) inhibits the growth of syngeneic tumors in vivo. Thus, the invention provides a method of treating cancer in a mammal subject by administering a therapeutically effective amount of an SLC to the mammal. SLCs useful in the methods of the invention include SLC polypeptides, variants and fragments and related nucleic acids. | 2016-03-03 |
| 20160058838 | Methods of Using Interleukin-10 for Treating Diseases and Disorders - Methods of treating subjects having a disease or disorder responsive to IL-10, including methods of administration and dosing regimens associated therewith, are provided. | 2016-03-03 |
| 20160058839 | LEPTIN FOR TREATING SYSTEMIC INFLAMMATORY RESPONSE SYNDROME - Provided are methods and compositions for reducing the severity of systemic inflammatory response syndrome (SIRS). The method comprises administering to an individual who has been diagnosed with SIRS, a composition comprising leptin. | 2016-03-03 |
| 20160058840 | Novel Administration Regime - The invention relates to a novel administration regime useful in the treatment of diseases or conditions where administration of insulin will be of benefit, as well as to kits for use in the same. In particular, the invention relates to a long-acting or ultra-long acting insulin for use in treating a disease or condition where administration of insulin will be of benefit, wherein the administration of said insulin comprises or consists of the following steps: (a) optionally providing a blood sample to be tested from an individual in need of treatment; (b) taking a single fasting blood (or plasma) glucose measurement from said individual in need of treatment; (c) using the single fasting blood (or plasma) glucose measurement to determine the insulin dose to be administered; and (d) administering the long-acting or ultra-long insulin to the individual at the dose determined in step (c). | 2016-03-03 |
| 20160058841 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE - An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug. | 2016-03-03 |
| 20160058842 | FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. | 2016-03-03 |
| 20160058843 | METHODS AND SYSTEM FOR INTERFERING WITH VIABILITY OF BACTERIA AND RELATED COMPOUNDS AND COMPOSITIONS - Provided herein are methods and systems for interfering with viability of bacteria and related compounds and compositions. | 2016-03-03 |
| 20160058844 | "Bilirubin Excretion Enhancer" - The purpose of the present invention is to establish a novel therapy method for hyperbilirubinemia and therefore, to provide a bilirubin excretion enhancer. The present invention provides a bilirubin excretion enhancer comprising, as an active ingredient, a serum albumin domain II-like protein comprising a serum albumin subdomain IIA. In one embodiment, the serum albumin subdomain IIA has an amino acid sequence of SEQ ID NO: 1. in one embodiment, the serum albumin domain II-like protein is a serum albumin domain II. In one embodiment, the serum albumin domain II comprises the amino acid sequence of SEQ ID NO: 4. | 2016-03-03 |
| 20160058845 | ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY - Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids. | 2016-03-03 |
| 20160058846 | THERAPEUTIC FOR TREATING CLOSTRIDIUM DIFFICILE INFECTION - The invention relates to deoxyribonuclease for use in the treatment of a suspected or existing | 2016-03-03 |
| 20160058847 | IS100- A Highly Effective Enzyme Principle For Use In Dermal Therapeutics, And For Health And Beauty - A aqueous preparation called IS 100 consisting of at least a hundred of proteins prepared from wheat germ lysate is provided. The preparation shows protease activity and is considerably stable. None of the constituent proteins in IS 100 can permeate synthetic or biological membranes and therefore IS 100 has a variety of in vitro or external applications that require cleaving and cleansing of unwanted or dead tissues on dermal surface. | 2016-03-03 |
| 20160058848 | TREATMENT OF CARDIO-RENAL DISEASE USING PCSK6 - A method of treating a cardio-renal disease is described that includes administering to a subject in need thereof a therapeutically effective amount of proprotein convertase subtilisin/kexin-6 (PCSK6), or an effective fragment thereof, which functions as a corin activator. | 2016-03-03 |
| 20160058849 | TREATMENT OF SYNUCLEINOPATHIES - This invention relates generally to treating synucleinopathies in subjects that are not clinically diagnosed with a lysosomal storage disease, as well as associated methods of making medicaments and screening methods. | 2016-03-03 |
| 20160058850 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASES OF INFECTIOUS AND NON-INFECTIOUS ORIGIN - The present invention is based, in part, on our analysis of C1-INH levels in various patient populations. Accordingly, in a first aspect, the invention features methods for assessing the protective capacity of endogenous C1-INH in a patient who has been diagnosed with ARDS, sepsis or a sepsis-related condition, a burn or a burn-related condition, SJS, CABG-related states and/or other traumatic injuries. The methods can include the steps of: (a) providing a fluid sample from the patient; (b) determining the amount of C1-INH functional activity in the sample; and (c) comparing the amount of C1-INH functional activity to a reference standard. Where the level of C1-INH functional activity is comparable to that within a healthy patient population, the patient's own protective capacity is compromised. | 2016-03-03 |
| 20160058851 | USE OF ANTAGONISTS OF GHRELIN OR GHRELIN RECEPTOR TO PREVENT OR TREAT STRESS-SENSITIVE PSYCHIATRIC ILLNESS - The invention relates to methods of protecting against chronic stress in a subject and treating stress sensitive disorders in a subject by antagonizing ghrelin or ghrelin receptor. | 2016-03-03 |
| 20160058852 | IMMUNOTHERAPY OF CANCER THROUGH COMBINATION OF LOCAL AND SYSTEMIC IMMUNE STIMULATION - Provided herein are compositions and methods for immunotherapy of cancers, said methods combining systemic vaccination with a recombinant expression vector encoding a viral antigen and/or a cancer specific tumor antigen(s) to induce activated CD8 T-cells, with a local (e.g., intratumoral) immune stimulation using standard or modified application of a TLR agonist, to induce local inflammatory and innate immune responses which recruit T-cells to the tumor. | 2016-03-03 |
| 20160058853 | INDIVIDUALIZED VACCINES FOR CANCER - The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient. | 2016-03-03 |
| 20160058854 | CANCER VACCINES AND VACCINATION METHODS - Compositions of multipeptide vaccines comprising at least seven tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from at least seven tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating gynecological and peritoneal cancers using such vaccines. | 2016-03-03 |
| 20160058855 | HIGH PURITY OVARIAN CANCER STEM CELLS FOR ACTIVE AUTOLOGOUS IMMUNE THERAPY - The disclosure provides cancer stem cells, for use in stimulating immune response against a cancer, such as ovarian carcinoma. Methods for preparing and purifying the cancer stem cells are provided. | 2016-03-03 |
| 20160058856 | ANTI-TUMOR DNA VACCINE - The present invention provides a pharmaceutical composition for treating a tumor, which is a micelle encapsulating at least one tumor-associated antigen gene. The present invention also provides a method for treating a tumor, comprising administering a micelle encapsulating at least one tumor-associated antigen gene to a patient in need of such treatment. | 2016-03-03 |
| 20160058857 | COSTIMULATION OF CHIMERIC ANTIGEN RECEPTORS BY MYD88 AND CD40 POLYPEPTIDES - The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen. The technology also relates to costimulation of therapeutic cells that express chimeric antigen receptors that recognize target antigens using chimeric MyD88- and CD40-derived polypeptides. The technology further relates in part to therapeutic cells that express chimeric antigen receptors, wherein the chimeric antigen receptors have an endodomain that includes MyD88- and CD40-derived polypeptides, and methods for treating patients using the modified therapeutic cells. | 2016-03-03 |
| 20160058858 | BLUETONGUE VIRUS VACCINE AND IMMUNOGENIC COMPOSITIONS, METHODS OF USE AND METHODS OF PRODUCING SAME - Provided are immunogenic and vaccine compositions and methods for their preparation and use, which compositions are effective in protecting against, minimizing the severity of, preventing, and/or ameliorating infection of ruminants with Bluetongue virus. Administration to an animal of at least one dose of an adjuvanted and twice inactivated Bluetongue virus composition as disclosed herein is effective in providing immunity to the animal and protection from infection with Bluetongue virus, thereby reducing the severity of and/or preventing disease caused by one or more strains or serotypes of Bluetongue virus. | 2016-03-03 |
| 20160058859 | IMMUNOGENIC COMPLEX FOR VACCINATION AND METHOD FOR THE PRODUCTION THEREOF - The present invention is related to an immunogenic complex comprising a polymerized antigen, mannan and a dialdehyde, the composition comprising it and the use thereof as an immune response stimulator and vaccine, useful in the treatment of infectious diseases, neoplasms and allergies. Likewise, the invention relates to the method for obtaining said immunogenic complex, based on the antigen and mannan simultaneous polymerization and conjugation by using a dialdehyde. | 2016-03-03 |
| 20160058860 | VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT - Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier. | 2016-03-03 |
| 20160058861 | PHOTOSYNTHETIC CELLULAR SUBSTANCES AND METHODS OF USE THEREOF - Systems and methods for developing and applying photosynthetic cellular substances to a human or animal for medical, therapeutic or cosmetic uses are provided. Photosynthetic cells, such as algal cells, can be used in these substances to provide the ability to continuously generate oxygen when exposed to a light source or other oxygen-generating trigger. The substances can be developed as a standalone liquid, gel or cream, or embedded within a bandage, mesh, scaffold or other structure with a light source to promote oxygen production. The substances can be applied topically for medical, therapeutic or cosmetic treatments, or injected internally for generation of oxygen within one or more parts of the body. | 2016-03-03 |
| 20160058862 | MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY - Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient. | 2016-03-03 |
| 20160058863 | LOW VISCOSITY CONCENTRATED PROTEIN DISPERSIONS - Disclosed herein are, inter alia, low viscosity dispersions comprising proteins and viscosity lowering agents; pharmaceutical compositions comprising low viscosity dispersions; and methods of making and using the pharmaceutical compositions and low viscosity dispersions. | 2016-03-03 |
| 20160058864 | Targeted Delivery of Anti-Fungal Agents - The present application discloses a targeting composition that actively targets chitin-like substances, such as those found in fungi, protists, arthropods, Alzheimer's plaques, etc. Methods are disclosed for preparation of chitin-targeted drug delivery vehicles composed of the targeting composition and one or more bioactive compounds. | 2016-03-03 |
| 20160058865 | STABLE TIGECYCLINE COMPOSITION - The present invention relates to a stable pharmaceutical composition of Tigecycline and process for the preparation of the same. The composition comprises Tigecycline and maltose wherein the pH of the bulk solution or solution after reconstitution is in between 3-6. | 2016-03-03 |
| 20160058866 | ALTERNATIVE SOLUTIONS FOR THE ADMINISTRATION OF CANNABIS DERIVED BOTANICAL PRODUCTS - Compositions comprising: (a) at least one polyvinylpyrrolidone/vinyl acetate copolymer that forms an open matrix network; and (b) at least one ingredient tetrahydrocannabinol and cannabidiol present within the open matrix network. | 2016-03-03 |
| 20160058867 | CROSSLINKED CHITOSAN-LACTIDE HYDROGELS - Aspects of the invention include crosslinked copolymer hydrogel compositions. Crosslinked copolymer hydrogel compositions according to certain embodiments include a copolymer of chitosan and a polyester and a hydrolysable crosslinker. In certain embodiments, crosslinked hydrogels further include fibrinogen. The subject invention also describes compositions having crosslinked copolymer hydrogels with one or more absorbed bioactive agents. Methods for preparing and using the crosslinked copolymer hydrogels of the invention are also described. | 2016-03-03 |
| 20160058868 | SOLID DOSAGE FORM CONTAINING ARABINOGALACTAN - Provided is a dosage form for delivery of a therapeutic agent comprising a polymer matrix comprising arabinogalactan and a therapeutic agent uniformly dispersed in said polymer matrix. In some embodiments, the dosage form is selected from the group consisting of a microsphere, a nanosphere, a powder, a tablet, a film or a pellet enclosed in a capsule. Also provided are methods for preparing the dosage form. | 2016-03-03 |
| 20160058869 | PALATABLE NUTRITIONAL COMPOSITION COMPRISING A NUCLEOTIDE AND/OR A NUCLEOSIDE AND A TASTE MASKING AGENT - The present invention relates to the use of a taste masking agent selected from the group of starch; cellulose; xanthan gum; gellan gum; alginate; galactomannans such as fenugreek, guar gum, tara gum, locust bean gum, and cassia gum; gum karaya; gum tragacanth; carrageenan; and mixture thereof, for improving one or more of mouth feel, taste, aftertaste and smell of a liquid aqueous nutritional composition comprising a nucleoside and/or a nucleotide. It also relates to a nutritional composition comprising an unsavoury nucleoside and/or nucleotide component, having improved sensory characteristics such as improved mouth feel, taste, aftertaste and smell. In particular, it relates to a composition comprising said unsavoury nucleoside and/or nucleotide component, in particular comprising an uridine-containing nucleoside and/or a nucleotide in combination with an unsavoury edible oil, such as a fish oil. | 2016-03-03 |
| 20160058870 | LIPOPEPTIDES FOR DELIVERY OF NUCLEIC ACIDS - Lipopeptide compounds having a central peptide and a lipophilic group attached to at least one terminus of the peptide, or to at least one amino acid residue of the peptide, and salts and uses thereof. The lipophilic group may be attached to the N-terminus, C-terminus or both termini of the peptide. The lipophilic group may be attached to at least one interal amino acid residue. The lipophilic group may be attached to either termini or both and at least one internal amino acid residue. | 2016-03-03 |
| 20160058871 | NOVEL PEPTIDE COMPLEXES - The invention relates to novel self-assembling peptide complexes comprising a charged peptide and a polysaccharide, methods of producing them and uses therefor. The novel self-assembling peptide complexes of the present invention have particular utility in the restoration of biomechanical or biochemical function of a variety of biological tissues, for example and without limitation, in degenerated spinal discs, osteoarthritic joints, damaged cartilage, meniscus, ligaments, tendons, dental, ophthalmic and cardiovascular and blood vessel tissues. The invention provides inter alia methods of repairing and or restoring biomechanical or biochemical function of biological tissues and scaffolds for the support of cell growth. | 2016-03-03 |
| 20160058872 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE - The description relates to imide-based compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type. | 2016-03-03 |
| 20160058873 | Cyclodextrin-Based Polymers for Therapeutic Delivery - Described herein are CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates. Also disclosed are methods of using (e.g., to treat a disorder) the CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates. | 2016-03-03 |
| 20160058874 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system disorder, cardiovascular disease, or metabolic disorder. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates. | 2016-03-03 |
| 20160058875 | TREATMENT OF CANCER - Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101. | 2016-03-03 |
| 20160058876 | Polyplexes - The present disclosure relates to compounds comprising (i) an active agent, wherein the active agent includes a charge at a predetermined pH, (ii) a polymer, wherein the polymer includes an opposite charge than the active agent at the predetermined pH; and (iii) a polyplex comprising the peptide and the polymer electrostatically bond together at the predetermined pH. In some embodiments, the active agent is a peptide, such as a peptide comprising MAPKAP kinase II inhibitory peptide, and in some embodiments the peptide includes a cell-penetrating peptide. In further embodiments, the disclosure provides methods for treating a disease or condition by administering a composition according to the present disclosure to a subject in need thereof. | 2016-03-03 |
| 20160058877 | REDUCTION OF ENDOTOXINS FROM POLYANIONIC POLYMER CONJUGATES - Described herein are methods of lowering the endotoxin content from a polyanionic polymer conjugate. In particular, methods of reducing the endotoxin content from a polyanionic polymer conjugate that can be useful for a variety of drug delivery applications are described herein. | 2016-03-03 |
| 20160058878 | Process for preparing a composition of pegylated proteins - This invention is in the field of protein pegylation. In particular, it relates to a method for pegylating therapeutic proteins. The invention also relates to the use of such pegylated therapeutic polypeptides for treating muscle diseases and disorders. | 2016-03-03 |
| 20160058879 | Growth Hormone Compound Formulation - The present inventions relates to compositions of growth hormone compounds, including pharmaceutical formulations. The compositions are able to provide initial and long term stability of the growth hormone compounds, rendering such compositions suited for use as a pharmaceutical formulation. | 2016-03-03 |
| 20160058880 | MINIMALLY TOXIC PRODRUGS - The present invention relates to the field of oligopeptide prodrugs that are intended for the treatment of cancer. The selectivity of these prodrugs requires the presence of an (oligo)peptidic moiety and/or a protective capping group to ensure the prodrug stability in blood. It further in particular relates to the exemplary oligopeptidic moiety ALGP and to prodrugs comprising it. In particular it also relates to the capping group phosphonoacetyl and to prodrugs comprising this capping group. | 2016-03-03 |
| 20160058881 | PRODRUGS WITH PROLONGED ACTION - A prodrug derivative of a bioactive peptide (or polypeptide) is provided that exhibits prolonged half-life in serum and prolonged action in vivo, compared to the parent peptide or polypeptide. In some embodiments, the peptide is selected from the group consisting of glucagon, exendin-4, GLP-1, GLP-2, GIP, vasoactive intestinal peptide (VIP), Pituitary adenylate cyclase-activating polypeptide 27 (PACAP-27), peptide histidine methionine (PHM), oxyntomodulin, secretin, osteocalcin, growth hormone releasing hormone, as well as analogs, derivatives and conjugates. | 2016-03-03 |
| 20160058882 | CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES - New ansamitocin derivatives bearing a linking group are disclosed. Also disclosed are methods for the synthesis of these new ansamitocin derivatives and methods for their linkage to cell-binding agents. The ansamitocin derivative-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents. | 2016-03-03 |
| 20160058883 | DRUG CONJUGATE COMPRISING ANTI-CDH3 (P-CADHERIN) ANTIBODY - It is an object of the present invention to provide a drug conjugate comprising an anti-CDH3 antibody that efficiently kills cancer cells expressing CDH3. According to the present invention, there is provided an immune complex formed by binding an antibody against CDH3 or a fragment thereof having CDH3 binding ability to a chemotherapeutic agent. | 2016-03-03 |
| 20160058884 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS - The present invention provides improved methods for formulating therapeutic compositions comprising an antibody drug conjugate (“ADC”) that reduce potency variability between batches of ADC and provide administration of such therapeutic compositions within a narrow intended range. | 2016-03-03 |
| 20160058885 | Antibodies With Immune Effector Activity and that Internalize In Folate Receptor Alpha-positive Cells - This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to FRA-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer cells; and methods of treating cancer using the antibodies. | 2016-03-03 |
| 20160058886 | PLATFORM FOR TARGETED DELIVERY TO STEM CELLS AND TUMOR CELLS AND USES THEREOF - The invention involves therapy and diagnostics using nanoparticles that provide targeted delivery of agents to cancer cells and stem cells, including cancer stem cells, the nanoparticles being pH sensitive and incorporating cytotoxic ceramides. | 2016-03-03 |
| 20160058887 | NANODIAMOND PARTICLE COMPLEXES - The present invention provides various functionalized nanodiamond particles. In particular, the present invention provides soluble complexes of nanodiamond particles and therapeutic agents, for example insoluble therapeutics, anthracycline and/or tetracycline compounds, nucleic acids, proteins, etc. The present invention also provides materials and devices for the controlled release of therapeutics, and methods for uses thereof. | 2016-03-03 |
| 20160058888 | Treatment of Operable High-Grade Glioma With Sitimagene Ceradenovec Gene Therapy and Ganciclovir - Gene therapy with genes for prodrug converting enzymes adds to local control of glioblastoma achieved by surgery. There appears to be a pronounced local reaction which is in part inflammatory and has a measurable immunological component. Considering the widely proven fact that during the weekslong gap-phase between surgery and completion of radiation or chemoradiation tumour growth from the infiltrative zone may continue unhampered, a treatment such as SIT will cover that time period. | 2016-03-03 |
| 20160058889 | PREVENTION OF MUSCULAR DYSTROPHY BY CRISPR/CAS9-MEDIATED GENE EDITING - Duchenne muscular dystrophy (DMD) is an inherited X-linked disease caused by mutations in the gene encoding dystrophin, a protein required for muscle fiber integrity. The disclosure reports CRISPR/Cas9-mediated gene editing (Myo-editing) is effective at correcting the dystrophin gene mutation in the mdx mice, a model for DMD. Further, the disclosure reports optimization of germline editing of mdx mice by engineering the permanent skipping of mutant exon (exon 23) and extending exon skipping to also correct the disease by post-natal delivery of adeno-associate virus (AAV). AAV-mediated Myo-editing can efficiently rescue the reading frame of dystrophin in mdx mice in vivo. The disclosure reports means of Myo-editing-mediated exon skipping has been successfully advanced from somatic tissues in mice to human DMD patients-derived iPSCs (induced pluripotent stem cells). Custom Myo-editing was performed on iPSCs from patients with differing mutations and successfully restored dystrophin protein expression for all mutations in iPSCs-derived cardiomyocytes. | 2016-03-03 |
| 20160058890 | SELECTIVE GENE THERAPY EXPRESSION SYSTEM - The present invention relates to an expression system for systemic administration comprising a sequence encoding a protein, said expression system allowing:
| 2016-03-03 |
| 20160058891 | IN VIVO ADCC MODEL - The present invention relates to a non-human animal comprising a humanized low affinity FcgR locus. Also provided herein is the use of said non-human animal for determining in vivo efficacy of antibodies, and methods for determining in vivo efficacy of antibodies. | 2016-03-03 |
| 20160058892 | PREPARATION OF BONE-SEEKING SUPERPARAMAGNETIC IRON NANOPARTICLES AS CONTRAST AGENTS AND METHODS FOR USING THE SAME - Described herein are compositions having a nanoparticle that is conjugated to at least one bone targeting moiety, wherein the bone targeting moiety is bonded to the nanoparticle by a linker, wherein the nanoparticle contains iron, and wherein the compositions are neutral or pharmaceutically acceptable salts or esters. Also described herein are methods of making these compositions. In one aspect, the nanoparticles serve as contrast agents for magnetic resonance imaging of bone metabolism. The compounds, compositions, and methods described herein can be used in a number of therapeutic applications including diagnosing or monitoring fracture and/or the progress of conditions associated with bone loss, which include, but are not limited to, osteoporosis, Paget's disease, osteolytic tumors, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, osteoarthritis, osteopenia, and hypercalcemia. | 2016-03-03 |
| 20160058893 | MICROPARTICLE COMPOSITIONS - There is provided a microparticle composition suitable for molecular imaging, the composition comprising microparticles, wherein the microparticles comprise: a core microparticle structure having a central area and a shell, and wherein the core microparticle structure comprises (i) a phosphatidylcholine lipid: (ii) a phosphatidylethanolamine lipid comprising at least one maleimide moiety; and (iii) an alkoxylated fatty acid. | 2016-03-03 |
| 20160058894 | RADIOLABELED PDE10A LIGANDS - Compounds of formula (I) are disclosed | 2016-03-03 |
| 20160058895 | RADIOLABELED GNRH ANTAGONISTS AS PET IMAGING AGENTS - Provided herein is technology relating to imaging agents for positron emission tomography (PET) and particularly, but not exclusively, to a gonadotropin-releasing hormone (GnRH) antagonist radiolabeled with positron emitting nuclides and to methods of visualizing GnRH receptors in the central nervous system by PET from administration of such compounds to warm-blooded animals for diagnostic purposes. | 2016-03-03 |
| 20160058896 | METHOD AND COMPOUND FOR TREATMENT OF CANCER USING PHOSPHOROUS-32 LABELED DNA - This invention provides a combination of a DNA strand/fragment and isotope therapy that is applied to a cancerous tissue to selectively kill cancer cells with minimal negative effects on surrounding non-cancerous cells. The mechanism of cancer cells uptake of large DNA fragment (larger than 30 bp) is endocytosis which does not occur in normal organ cells. We are the first to identify this difference and use the selectivity to deliver isotope P-32 to treat cancer. The DNA fragments with labeled isotope are able to be absorbed by the tumor cells and bind the tumor cell's DNA through recombination, and then the isotope kills the tumor cells. Illustratively, a gene or a DNA fragment is employed as a carrier to deliver the P-32 which can kill cancer cells through radioactive emission. Appropriate doses are provided to patients as part of a medical treatment method. | 2016-03-03 |
| 20160058897 | KIT AND METHOD FOR QUICKLY PREPARING RADIO-ISOTOPE LABELED HUMAN SERUM ALBUMIN MICROSPHERES - The present disclosure relates to a kit for preparing radio-isotope labeled human serum albumin (HSA) microspheres, which includes: a container (A), containing SnCl | 2016-03-03 |
| 20160058898 | DIAGNOSIS OF PROSTATE CANCER - Methods for diagnosing prostate cancer, and differentiate prostate cancer from other prostate complications, and use of said method, and diagnosing and monitoring lymph gland metastasis, post-operative examinations, and examinations during or after radiation, cytostatic, and androgen treatments are disclosed. The methods comprise injecting tracer-labelled PSA or hK2 specific antibodies, visualising PSA or hK2 producing tissue with the aid of a visualisation method, and diagnosing prostate cancer from the difference in visualisation. | 2016-03-03 |
| 20160058899 | Time Release Biocide Dispensing Device - A time release biocide dispensing device for controllably dispensing biocide into a condensation line of an air conditioner at predetermined concentrations and volumes over a duration. The device utilizes principles of pressure equilibrium and material resistance to dispense a regulated and steady flow of the biocide into the line. The device utilizes a controller, a pump, a container, a fluid tube, and a coupling member. The device is configured to easily attach to the line and facilitate setting of the controller, such that minimal tools and expertise are needed for operation. A container attaches to the line and holds a biocide and a volume having a vacuum. A pump forces a fluid into the vacuum to disturb the equilibrium, and thus partially force the biocide into the line. A resistance member restricts the flow to drops to further regulate the flow of the biocide into the line. | 2016-03-03 |
| 20160058900 | ENDOSCOPE REPROCESSOR - An endoscope reprocessor includes an immersion tank, a convex-shaped groove, a lid portion, a liquid supply section, a discharge port as an opening from which the liquid is discharged and which is provided at the liquid supply section, the discharge port being arranged such that a part of the opening is opposed to a side surface of the convex-shaped groove, and a control section that drives the liquid supply section to allow the liquid to be introduced into the immersion tank up to a first water level at which a flat portion of the lid portion is immersed in the liquid, and to allow the liquid to be discharged toward the flat portion and the side surface through the discharge port at the first water level. | 2016-03-03 |
| 20160058901 | Chlorine Dioxide Decontamination System and Methods - A scalable, portable and modular chlorine dioxide fumigant decontamination system having an activating area and a neutralizing area which may be housed separately or as a single operationally connected unit, and which may be configured as a closed loop system connected to a decontamination chamber for decontamination of articles, or as an open loop system for decontamination of interiors and large confined spaces, and employing a specialized activating cup that is permeable to air yet substantially impermeable to water and chlorine dioxide reaction by-products such that directing air through the activation cup releases nearly pure chlorine dioxide fumigant. Methods and articles relating to the system are also described. | 2016-03-03 |
| 20160058902 | PACKAGING AND TRANSPORTATION KIT FOR HYDROGEN PEROXIDE OR OTHER CHEMICAL PRODUCT USED IN STERILIZATION OR DISINFECTION EQUIPMENTS AND RESPECTIVE SUPPLYING SYSTEM - The present invention refers to a Packaging and transportation kit for hydrogen peroxide or other chemical products used as sterilizing or disinfecting agents in sterilization or disinfection equipment that prevents leakage of the product. | 2016-03-03 |
| 20160058903 | PREFABRICATED ALGINATE-DRUG BANDAGES - The invention provides a solution to the drawbacks associated with conventional alginate dressings. This invention features improved alginate dressings or bandages as well as a fabrication process that results in an alginate sheet that is preloaded with drug, can be stored in a freeze-dried state, and is compliant and ready to use at the time of administration. | 2016-03-03 |
| 20160058904 | CHITOSAN-BASED HEMOSTATIC TEXTILE - A microfibrillar high molecular weight chitosan-based textile can be used as a hemostat. The chitosan has been treated in a nitrogen field by applying energy to ionize nitrogen in and around the chitosan textile. A single or multiple such treatments may be employed. For example, the chitosan textile may be irradiated under nitrogen using γ-irradiation, treated under a nitrogen plasma, or both. | 2016-03-03 |
| 20160058905 | RADIOACTIVE BONE CEMENT - A target tissue can be treated with a radioisotope. Some methods for treating a target tissue with a radioisotope include determining a distance between a target tissue and a surface of a matrix material to be positioned adjacent the target tissue and, based on the determined distance, determining an activity to be mixed with the matrix material to obtain a desired activity concentration. Some methods further include mixing the radioisotope with the matrix material. In some embodiments, the matrix material comprises bone cement, and the target tissue is a tumor in a bone. The radioisotope may be a beta-emitting radioisotope mixed in the cement at a concentration to form a radioactive cement. | 2016-03-03 |
| 20160058906 | BONE TREATMENT SYSTEMS AND METHODS - The present disclosure relates to bone cement formulations that have an extended working time for use in vertebroplasty procedures and other osteoplasty procedures together with cement injectors that include energy delivery systems for on-demand control of cement viscosity and flow parameters. The bone cement formulations may include a liquid component having at least one monomer and a non-liquid component including polymer particles and benzoyl peroxide (BPO). The non-liquid component may be further configured to allow controlled exposure of the BPO to the liquid monomer so as to enable control of the viscosity of the bone cement composition. | 2016-03-03 |
| 20160058907 | BIOMATERIAL COMPOSITIONS - Biomaterial compositions comprising organosilicon monomers (such as silorane monomers) and chemical curing systems or dual chemical/light curing systems, in conjunction with optional tetraoxaspiro[5.5]undecanes (“TOSUs”) and/or fillers. | 2016-03-03 |
| 20160058908 | METHOD FOR PRODUCING LAMINATE OF SHEET-SHAPED CELL CULTURE AND FIBRIN GEL - A laminate of a sheet-shaped cell culture is disclosed, which has excellent operability and is suitable for implantation. A method is disclosed for producing a laminate of a fibrin gel and a sheet-shaped cell culture, including a step of dripping a liquid containing fibrinogen onto an upper surface of a sheet-shaped cell culture, a step of spraying a liquid containing thrombin onto the surface, and a step of forming a fibrin gel layer on the surface by a reaction between fibrinogen and thrombin; and a laminate of a fibrin gel and a sheet-shaped cell culture produced by the method are disclosed. | 2016-03-03 |
| 20160058909 | MIMETIC TISSUE STRUCTURE CONTAINING EXTRACELLULAR MATRIX PROTEIN-BONE MINERAL COMPLEX AND METHOD FOR MANUFACTURING SAME - Provided are a tissue structure mimetic used for regenerating a tissue and a method for manufacturing the same, and more particularly, a 3-dimensional tissue structure mimetic which consists of a complex of extracellular matrix protein and bone mineral, wherein the complex is specifically bound to a regeneration-functional peptide to thereby be capable of implementing environment of a tissue requiring restoration, and a method for manufacturing the same. In the tissue structure mimetic according to the present invention, bone mineral components are finely dispersed in the extracellular matrix protein to have excellent mechanical strength of the tissue structure mimetic and conductivity which provides a migration path of cells involved in tissue regeneration. Further, environment of the tissue may be implemented by the peptide contained in the tissue structure mimetic to finally remarkably increase tissue regeneration capacity. | 2016-03-03 |
| 20160058910 | METHOD FOR PREPARING PARTICULATE DECELLULARIZED TISSUE - A particulate decellularized tissue is provided which shows sufficiently effective tissue regeneration and does not show cytotoxicity when used as material for cell culture. In accordance with the method for preparing a particulate decellularized tissue comprising a step of applying a high hydrostatic pressure to animal-derived tissues in a medium, a particulate decellularized tissue is obtained which does not show cytotoxicity but shows the effect of cellular attraction and the effect of induction of cellular differentiation and shows a high effect of tissue regeneration. | 2016-03-03 |
| 20160058911 | MULTI-STEP METHOD FOR FABRICATING TISSUE ENGINEERING BONE - A multi-step method for fabricating a tissue engineering bone comprises the following steps: (1) scaffold repair and pre-vascularization: fabricating a tissue engineering bone scaffold at a bone defect site, and conducting pre-vascularization; and (2) post-implantation of a seed cell for bone tissue engineering: after an inflammatory reaction period, combined with time for micro-vessel in-growth, implanting an osteogenic-induced seed cell into a tissue engineering bone scaffold at the bone defect site. In certain embodiments, the step (2) of post-implantation of a seed cell for bone tissue engineering is performed 7 to 14 days after the step (1) of scaffold repair and pre-vascularization. The method can be used to rapidly fabricate a large section of tissue engineering bone, greatly reduce usage of the seed cell for bone tissue engineering required in repair of per unit volume of bone tissue, and improve the utilization rate of the seed cell. | 2016-03-03 |
| 20160058912 | SCAFFOLDS FOR PROMOTING CALCIFIED CARTILAGE AND/OR BONE FORMATION - Biomimetic hydrogel and selected ceramic interface scaffolds useful in regenerating calcified cartilage and promoting stable and integrative cartilage repair are provided. An aspect of this application relates to scaffolds for promoting calcified cartilage and/or bone formation. The scaffolds of this application comprise a biomimetic hydrogel and a ceramic structure or mineral source selected to modulate biosynthesis and mineralization of chondrocytes. | 2016-03-03 |
| 20160058913 | ANTI-THROMBOGENIC GRAFTS - The present invention provides anti-thrombogenic compositions, including anti-thrombogenic vascular grafts. In certain embodiments, the compositions comprise decellularized tissue coated with an anti-thrombogenic coating. The present invention also provides methods of preparing anti-thrombogenic compositions and methods of treatment comprising implanting the anti-thrombogenic compositions into a subject in need thereof. | 2016-03-03 |
| 20160058914 | Gastrointestinal Device With Associated Microbe-Promoting Agents - A gastrointestinal device and methods of manufacturing said gastrointestinal device are described and include a flexible tubular structure including an inner surface and an outer surface, at least one microbe-promoting agent associated with at least one of the inner surface and the outer surface, the at least one microbe-promoting agent configured to promote attraction, colonization, and growth of at least one type of commensal microbe, and a proximal end and a distal end, the proximal end and the distal end forming a flow conduit through the flexible tubular structure; and at least one anchor structure including one or more gastric wall-engaging components configured to engage a wall of the gastrointestinal tract of the subject. | 2016-03-03 |
| 20160058915 | Medical Balloon Coated With Therapeutic Agent, Carboxylic Acid, and Salt Thereof - A coated medical balloon that includes a polymeric material having a surface with a therapeutic agent-containing mixture coated thereon, wherein the mixture includes a therapeutic agent, an unsaturated carboxylic acid, and a salt of the unsaturated carboxylic acid. | 2016-03-03 |
| 20160058916 | LOCAL DELIVERY OF WATER-SOLUBLE OR WATER-INSOLUBLE THERAPEUTIC AGENTS TO THE SURFACE OF BODY LUMENS - A method and device for local delivery of water-soluble or water-insoluble therapeutic agents to the surface of a normal or diseased body lumen is disclosed. An expandable structure of a medical disposable device, such as a balloon of a balloon catheter, is coated with an amphiphilic polymer coating comprising a therapeutic agent and an amphiphilic polymer or co-polymer. The medical disposable device is inserted into a body lumen, and expanded to contact the amphiphilic polymer coating against the body lumen. The total solubility of the polymer or co-polymer in vivo prevents any embolic hazard associated with the amphiphilic polymer coating. | 2016-03-03 |
| 20160058917 | Adhesion Preventing Material - An object of the present invention is to provide an adhesion preventing material capable of preventing adhesion safely and efficiently. The present invention provides an adhesion preventing material comprised of a cell sheet containing mesothelial cells; an adhesion preventing method and organ regeneration promoting method each using the cell sheet containing mesothelial cells. | 2016-03-03 |
| 20160058918 | LUBRICIOUS ONE-PART HYDROPHILIC COATINGS - A lubricious coating for use on an implantable medical device includes a heterochelic component, a homotelechelic polymer and biocompatible initiator. Methods of forming such lubricious coatings are also provided. | 2016-03-03 |
| 20160058919 | METAL MEDICAL DEVICE - The present invention provides metal medical devices which are provided with sliding properties (lubricity), low protein adsorption properties and low cell adsorption properties and further in which these properties are prevented from deteriorating. The present invention relates to a metal medical device having a surface at least partially treated with a copolymer C of a polymerizable silane compound A and a polymerizable compound B that contains a functional group. | 2016-03-03 |
| 20160058920 | Method for Treating Surface of Implant - Disclosed is a method for treating a surface of an implant. The disclosed method for treating the surface of the implant comprises the steps of: coating a surface treatment composition containing an organic material having a hydrophilic group on the surface of the implant (coating step); and drying the coated surface treatment composition (drying step). | 2016-03-03 |
| 20160058921 | Antimicrobial examination gloves - A method of manufacturing nitrile rubber latex medical examination gloves during which (a) the glove formers are dipped into a coagulant solution containing divalent calcium cations and calcium nitrate particles, to which has been added a composition comprising Alcohol ethoxylate, Amine oxide, Ethylenediaminetetracetic acid, Glutaraldehyde, Chlorhexidine di-gluconate, Chlorhexidine di-hydrochloride, Salisept, Titanium Dioxide, nano particle silver; and during which (b) the coated glove formers are then dipped into a nitrile rubber latex dispersion to which has been added a composition comprising Alcohol ethoxylate, Amine oxide, Lactic acid, Ethylenedi-aminetetracetic acid, Glutaraldehyde, Salisept; and during which (c) the nitrile rubber latex gloves are finally placed in to packaging utilising a clear coat varnish that it is impregnated with a phenolic chlorine compound, micronised nanosilver colloid, and a quaternary compound. | 2016-03-03 |
| 20160058922 | METHOD FOR DRUG LOADING HYDROXYAPATITE COATED IMPLANT SURFACES - A method for loading a hydroxyapatite coated implant with a therapeutic agent including the steps of providing an implant and applying a hydroxyapatite coating on a surface of the implant. The hydroxyapatite coated implant is contacted with a solution including the therapeutic agent. The hydroxyapatite coated implant and solution is heated to temperature of about 60° C. to about 100° C. Pressure is applied to the hydroxyapatite coated implant and solution from about 2 bar to about 10 bar, to load the hydroxyapatite coated implant with the therapeutic agent. An implant made ac cording to the method has sustained therapeutic agent delivery and includes a base and a biomimetic hydroxyapatite coating disposed on a surface thereof. | 2016-03-03 |
| 20160058923 | Compositions and Methods for Reducing Neointima Formation - Compositions, devices, grafts and methods for reducing or preventing anti-neointima following cardiovascular injuries and interventions are disclosed. The compositions, devices, and grafts typically include an effective amount of a CTP synthase 1 inhibitor to reduce proliferation of vascular smooth muscle cells, without substantial reducing the proliferation of endothelial cells. Methods of reducing neointima formation, accelerating re-endothelialization, and reducing restenosis in a subject using the compositions, devices, and grafts are also disclosed. | 2016-03-03 |
